MX2016016612A - Formulaciones estables de undecanoato de testosterona. - Google Patents

Formulaciones estables de undecanoato de testosterona.

Info

Publication number
MX2016016612A
MX2016016612A MX2016016612A MX2016016612A MX2016016612A MX 2016016612 A MX2016016612 A MX 2016016612A MX 2016016612 A MX2016016612 A MX 2016016612A MX 2016016612 A MX2016016612 A MX 2016016612A MX 2016016612 A MX2016016612 A MX 2016016612A
Authority
MX
Mexico
Prior art keywords
testosterone undecanoate
stable formulations
directed
present
pharmaceutical formulations
Prior art date
Application number
MX2016016612A
Other languages
English (en)
Inventor
G Schoonus-Gerritsma Gerritdina
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016016612A publication Critical patent/MX2016016612A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Abstract

La presente invención se relaciona a formulaciones farmacéuticas estables; más específicamente, la presente invención se relaciona con formulaciones farmacéuticas estables de undecanoato de testosterona.
MX2016016612A 2014-06-17 2015-06-15 Formulaciones estables de undecanoato de testosterona. MX2016016612A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14172805 2014-06-17
PCT/EP2015/063292 WO2015193224A1 (en) 2014-06-17 2015-06-15 Stable formulations of testosterone undecanoate

Publications (1)

Publication Number Publication Date
MX2016016612A true MX2016016612A (es) 2017-03-20

Family

ID=50980940

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016612A MX2016016612A (es) 2014-06-17 2015-06-15 Formulaciones estables de undecanoato de testosterona.

Country Status (12)

Country Link
US (1) US9925200B2 (es)
EP (1) EP3157505B1 (es)
JP (1) JP6618488B2 (es)
KR (1) KR20170020779A (es)
CN (1) CN106456782B (es)
AU (1) AU2015276321B2 (es)
BR (1) BR112016028192A2 (es)
CA (1) CA2950670A1 (es)
ES (1) ES2749008T3 (es)
MX (1) MX2016016612A (es)
RU (1) RU2708238C2 (es)
WO (1) WO2015193224A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018374029B2 (en) 2017-11-27 2024-01-11 Umecrine Cognition Ab Pharmaceutical formulation of 3a-ethynyl-3B-hydroxyandrostan-17-one oxime

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098802A (en) 1975-02-18 1978-07-04 Akzona Incorporated Oral pharmaceutical preparation having androgenic activity
US4147783A (en) 1974-02-28 1979-04-03 Akzona Incorporated Oral pharmaceutical preparation
NL189235C (nl) 1974-02-28 1993-02-16 Akzo Nv Werkwijze voor de bereiding van een oraal toe te dienen farmaceutisch preparaat met androgene werking.
NL7510104A (nl) 1975-08-27 1977-03-01 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
ATE113471T1 (de) 1989-08-17 1994-11-15 Cortecs Ltd Arzneiformulierungen.
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
SI0999826T1 (en) 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US7396526B1 (en) * 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
AU768537B2 (en) 1999-04-01 2003-12-18 Merck Sharp & Dohme B.V. Formulation comprising testosteron undecanoate and castor oil
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6652880B1 (en) * 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
RU2303981C2 (ru) * 2000-11-01 2007-08-10 Юнимед Фармасьютикалс, Инк. Способ лечения эректильной дисфункции и повышения либидо у мужчин
AU2005309808A1 (en) * 2004-11-24 2006-06-01 Merck & Co., Inc. Liquid and semi-solid pharmaceutical formulations for oral administration of a substituted amide
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2006113505A2 (en) 2005-04-15 2006-10-26 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
CA2822435C (en) * 2009-12-31 2018-09-11 Differential Drug Development Associates, Llc Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
RU2012142997A (ru) * 2010-04-12 2014-06-20 Кларус Терапеутикс, Инк. Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
US20120135074A1 (en) * 2010-11-30 2012-05-31 Chandrashekar Giliyar High-Strength Testosterone Undecanoate Compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
EP2968366A4 (en) 2013-03-15 2016-09-07 Clarus Therapeutics Inc METHODS OF TREATING TESTOSTERONE DEFICIENCY
WO2015100406A1 (en) 2013-12-26 2015-07-02 Clarus Therapeutics, Inc. Use of oral pharmaceutical products combining testosterone esters with hypolipidemic agents

Also Published As

Publication number Publication date
US9925200B2 (en) 2018-03-27
WO2015193224A1 (en) 2015-12-23
AU2015276321A1 (en) 2016-11-10
ES2749008T3 (es) 2020-03-18
KR20170020779A (ko) 2017-02-24
EP3157505A1 (en) 2017-04-26
EP3157505B1 (en) 2019-07-24
RU2017101240A3 (es) 2019-02-22
US20170136033A1 (en) 2017-05-18
BR112016028192A2 (pt) 2017-08-22
RU2708238C2 (ru) 2019-12-05
CN106456782A (zh) 2017-02-22
JP2017522283A (ja) 2017-08-10
AU2015276321B2 (en) 2019-10-24
CN106456782B (zh) 2020-02-18
JP6618488B2 (ja) 2019-12-11
RU2017101240A (ru) 2018-07-17
CA2950670A1 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
PH12018500950A1 (en) Subcutaneous formulations of anti-cd38 antibodies and their uses
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
MX2017006217A (es) Polinucleotidos moduladores.
TW201614041A (en) Compositions for electronic devices
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
TWD171711S (zh) 端子
PH12017500836A1 (en) Transdermal formulations
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
IN2013MU00848A (es)
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
IN2013MU03641A (es)
SG10201900598TA (en) Factor viii formulation
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
IN2014CH00840A (es)
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
IN2014CH00151A (es)
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
NZ721832A (en) Solid forms of tenofovir
MX2016016612A (es) Formulaciones estables de undecanoato de testosterona.
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
MA40444A (fr) Procédé de préparation de formulations de poudre sèche
EA201692453A1 (ru) Способ получения ингаляционных составов
MX2017003165A (es) Jabones antimicrobianos que contienen carvacrol y metodos de uso de los mismos.
EP3177280A4 (en) Synthesis of 2,2,2-trifluoroethanethiol
IN2013MU03768A (es)

Legal Events

Date Code Title Description
FG Grant or registration